TY  - JOUR
AU  - Saiz, Maria Laura
AU  - Lozano-Chamizo, Laura
AU  - Florez, Aida Bernardo
AU  - Marciello, Marzia
AU  - Diaz-Bulnes, Paula
AU  - Corte-Iglesias, Viviana
AU  - Bernet, Cristian Ruiz
AU  - Rodrigues-Diez, Raul R
AU  - Martin-Martin, Cristina
AU  - Rodriguez-Santamaria, Mar
AU  - Fernandez-Vega, Ivan
AU  - Rodriguez, Ramon M
AU  - Diaz-Corte, Carmen
AU  - Suarez-Alvarez, Beatriz
AU  - Filice, Marco
AU  - Lopez-Larrea, Carlos
PY  - 2024
DO  - 10.1016/j.biopha.2024.116492
UR  - http://hdl.handle.net/20.500.12105/20070
AB  - Targeting epigenetic mechanisms has emerged as a potential therapeutic approach for the treatment of kidney diseases. Specifically, inhibiting the bromodomain and extra-terminal (BET) domain proteins using the small molecule inhibitor JQ1 has shown...
LA  - eng
PB  - Elsevier
KW  - Azepines
KW  - Reperfusion Injury
KW  - Triazoles
KW  - Renal Insufficiency, Chronic
KW  - Disease Progression
KW  - Mice, Inbred C57BL
KW  - Kidney
KW  - Liposomes
KW  - Bromodomain Containing Proteins
KW  - Nuclear Proteins
KW  - Animals
KW  - Mice
KW  - Male
KW  - Transcription Factors
KW  - Acute Kidney Injury
KW  - Disease Models, Animal
KW  - Nanoparticles
KW  - Cell Cycle Proteins
TI  - BET inhibitor nanotherapy halts kidney damage and reduces chronic kidney disease progression after ischemia-reperfusion injury.
TY  - journal article
ER  -